Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Presence of a suitable related HLA-haploidentical bone marrow donor.a. The donor and recipient must be identical at at least one allele of each of the following genetic loci: HLA-A, HLA-B, HLA-Cw, HLA-DRB1, and HLA-DQB1. A minimum match of 5/10 is therefore required, and will be considered sufficient evidence that the donor and recipient share one HLA haplotype. 1 year-50 years Patients must have a confirmed histopathologic diagnosis and be classified as high risk defined by having an expected survival of \< 10%. Examples include: * Neuroblastoma or ganglioneuroblastoma * Failure to achieve at least a PR after induction therapy with COG ANBL0532 or standard chemotherapy * Refractory to induction chemotherapy with COG ANBL0532 or standard chemotherapy * Patients with high risk disease as defined in Appendix 1 whose autologous peripheral blood stem cell product is contaminated with neuroblastoma or who do not have an autologous product available * Patients with high risk disease as defined in Appendix 1 who do not meet eligibility requirements/organ function requirements for myeloablative conditioning. Patients with \>5 identified lesions on the end of induction (COG ANBL0532 or standard chemotherapy) MIBG scan * Stage 4 rhabdomyosarcoma * Metastatic Ewing Sarcoma * Osteosarcoma with metastatic disease beyond the lungs and/or with lung metastases not amenable to resection * Desmoplastic small round cell tumor * Any other solid tumor and soft tissue sarcoma with an e…